• 17 Mar, 2026

Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 9, 2026 -- Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced that Tom Barnes, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:00 AM PT in San Francisco.

About Averna Therapeutics

Averna is a biotechnology company developing genomic medicines designed to insert any gene or genetic instruction of interest safely and efficiently into "safe harbor" sites in the genome. Our platform configures a modular, all-RNA system combined with multiple LNP delivery solutions. This proprietary approach has the potential to expand the reach of genomic medicines, increasing the scope of addressable diseases including cancer, autoimmune and rare genetic diseases – broadening the patient populations able to benefit from this potentially life-changing class of therapies. For more information, please visit www.avernatx.com.

This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology. 

PR Newswire

PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals.